

Verve Wellness Inc. operates as a telehealth-focused medical weight loss clinic serving patients throughout New York and Connecticut, delivering GLP-1 receptor agonist therapy through virtual consultations with board-certified providers. The clinic structures its services around semaglutide prescribing for patients seeking medically supervised weight reduction, eliminating the need for in-person office visits while maintaining clinical oversight through digital health platforms. Based in New York, NY, Verve Wellness positions itself within the expanding telehealth weight management sector by offering access to prescription weight loss medications that were previously available primarily through traditional brick-and-mortar endocrinology or obesity medicine practices.
The clinical protocol at Verve Wellness centers on semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that functions by mimicking incretin hormones to regulate appetite and glucose metabolism. Patients receive individualized dosing schedules that typically begin with lower subcutaneous injection doses and titrate upward based on tolerance and response, following established clinical guidelines for this medication class. The telehealth model allows providers to monitor patient progress through regular virtual check-ins, adjust dosing protocols remotely, and address side effects such as nausea or gastrointestinal changes that commonly occur during the initial titration phase. Verve Wellness coordinates medication fulfillment through partner pharmacies, streamlining the process from prescription to delivery for patients in both New York and Connecticut who meet clinical eligibility criteria including BMI thresholds and absence of contraindications like personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
The provider team at Verve Wellness consists of board-certified clinicians licensed to practice medicine in New York and Connecticut, ensuring compliance with state-specific telemedicine regulations and prescribing requirements. These providers conduct comprehensive initial assessments that include medical history review, current medication reconciliation, evaluation of previous weight loss attempts, and screening for conditions that may impact semaglutide safety or efficacy such as diabetic retinopathy, pancreatitis history, or renal impairment. The clinical approach emphasizes that semaglutide therapy functions as one component of a broader weight management strategy, with providers offering guidance on nutrition modifications, physical activity integration, and behavioral factors that influence long-term weight maintenance beyond the active medication phase.
Patients enrolling with Verve Wellness can expect an intake process conducted entirely through secure video platforms, beginning with completion of digital health questionnaires and upload of relevant medical records or laboratory results. Initial consultations typically involve discussion of realistic weight loss expectations, review of the injection technique for subcutaneous administration, and establishment of a monitoring schedule that includes regular weigh-ins and symptom tracking. The ongoing care model includes scheduled follow-up appointments at intervals determined by individual patient needs and medication titration schedules, with providers available for interim questions or concerns through the clinic's patient portal. This continuity of care structure addresses one of the primary challenges in telehealth weight management—maintaining accountability and clinical oversight when patients are not physically present in a medical office.
The telehealth delivery model distinguishes Verve Wellness from traditional weight loss clinics by removing geographic barriers for patients across New York and Connecticut who may lack convenient access to obesity medicine specialists in their immediate area. The clinic's focus on GLP-1 therapy specifically, rather than offering a broad menu of weight loss interventions, allows for specialized expertise in managing this medication class and its associated considerations. Patients benefit from the convenience of receiving care from home or work locations while maintaining access to licensed medical providers who can prescribe, monitor, and adjust therapy based on individual response patterns. This streamlined approach serves patients seeking medical weight loss intervention who prefer virtual care delivery and meet the clinical criteria for semaglutide therapy as determined through comprehensive telehealth evaluation.

· Board-Certified NP & RN
MyPeptideMatch.com is an independent directory. We do not provide medical advice. Always consult a qualified healthcare provider before starting any peptide therapy.


